1Documented transfusion transmission of West Nile virus raised concern regarding transfusion-transmitted DENV.
2In the Caribbean, DENV is also epidemic and responsible for severe thrombocytopenia.
3These studies establish a role for nutritional status in DENV disease severity.
4These results reflect our recent findings in a mouse model of DENV cross-protection.
5No behavioral or demographic factors were significantly associated with DENV infection.
6The mechanism by which DENV infects the host cell remains unclear.
7Here we review the strategies to identify inhibitors for DENV therapy.
8We show that immature DENV is infectious in cells expressing DC-SIGN.
9Neither vaccine nor effective therapeutics is currently available for DENV.
10Skin immune cells are an important component of initial DENV infection and systemic spread.
11To date, no vaccines or antiviral therapeutics have been approved for combating DENV-associated disease.
12Dengue virus (DENV) is the most common arthropod-borne viral disease of humans.
13Overall, the cross-reactive B cell immune response dominates during secondary DENV infections in humans.
14Conclusions: Southeast Asia countries were found to be the possible source of DENV in Guangzhou.
15Therefore, we carried out a comprehensive investigation into the molecular characteristics of the DENV-3 involved.
16Interestingly, DENV strains from different years had different origins.